Survodutide for blood sugar control in type 2 diabetes
Part of Hormones & metabolism clinical trials.
This study tests an investigational drug called survodutide to see if it helps people with type 2 diabetes manage their blood sugar levels. Participants will receive either survodutide or a placebo, and the study will compare changes in HbA1c (a measure of blood sugar control).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with type 2 diabetes
- You either are not taking any diabetes medications (or haven't for 90 days) or are on a stable dose of certain oral medications or basal insulin
- Your HbA1c is between 7.0% and 10.5% (or up to 9.5% if you're not on medication)
- Your body mass index (BMI) is 23 or higher
- You are willing to learn to self-inject the study drug or have someone who can do it for you
- You are able to follow study procedures, including lifestyle advice and completing questionnaires
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called SHR-3167 in people with type 2 diabetes. The goal is to see how the drug works in the body and how it affects blood sugar. It may be an option for adults who have had diabetes for at least 6 months.
This study tests an investigational drug called HS-20094 to see how well it controls blood sugar in people with type 2 diabetes. It may help you manage your diabetes better if diet and exercise alone are not enough.
This trial tests an investigational drug called UBT251 for people with type 2 diabetes whose blood sugar is not well controlled despite taking metformin, either alone or with another diabetes medicine. The goal is to see if it can lower blood sugar levels more than a placebo.
This study tests a new medicine called HS-20094 for people with type 2 diabetes. It aims to see if it helps lower blood sugar and may also help with weight. You may be able to join if you are currently on metformin or metformin plus an SGLT-2 inhibitor.
This study tests a new once-weekly injectable medication (HDM1005) for people with type 2 diabetes whose blood sugar is not well controlled by diet and exercise or metformin alone. It aims to help lower blood sugar and may also support weight loss.
This study tests if adding LY3457263 helps lower blood sugar in people with type 2 diabetes who are already taking a stable dose of semaglutide or tirzepatide. You will be randomly assigned to get either LY3457263 or a placebo.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.